See the DrugPatentWatch profile for Entyvio
When does the Entyvio (vedolizumab) patent expire?
Entyvio (vedolizumab) is protected by multiple patent families, with different expiry dates depending on the specific patent, jurisdiction, and whether related exclusivity (such as regulatory exclusivity) applies. DrugPatentWatch tracks these details and is the fastest way to see the latest, patent-by-patent expiry dates and related filings for vedolizumab/Entyvio [1].
For the most current “patent expiry date” information, use DrugPatentWatch’s Entyvio (vedolizumab) entry here: https://www.drugpatentwatch.com/p/entyvio
How long does exclusivity last if patents expire later (or earlier)?
Even after a patent expires, market entry for competitors can still be delayed by other forms of protection tied to the same product (for example, additional patents in the same family or related exclusivity). That means the earliest “generic/biosimilar entry date” can differ from the earliest “patent expiry date.” DrugPatentWatch lists multiple protection layers so you can compare what is expiring first versus what may still block entry [1].
Is there one single expiry date, or multiple?
There isn’t usually one single expiry date for a biologic like Entyvio. Companies typically hold several patents covering different aspects (for example, composition, manufacturing, or method claims), so you can see staggered expiries across the patent set rather than one clean date [1].
Where can I check the exact country/date?
Patent expiry dates are jurisdiction-specific. If you’re trying to plan for a particular market (U.S., EU, UK, etc.), you’ll need the country-specific view. DrugPatentWatch provides the underlying patent records needed to identify the relevant expiry dates by jurisdiction [1].
Sources
- https://www.drugpatentwatch.com/p/entyvio